

Ref: FOI/GS/ID 8734

**Please reply to:**  
FOI Administrator  
Trust Management  
Maidstone Hospital  
Hermitage Lane  
Maidstone, Kent  
ME16 9QQ  
Email: [mtw-tr.foiadmin@nhs.net](mailto:mtw-tr.foiadmin@nhs.net)  
[www.mtw.nhs.uk](http://www.mtw.nhs.uk)

27 December 2023

## **Freedom of Information Act 2000**

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Nivolumab.

*You asked: All questions are shown as received by the Trust.*

*Q1. In the last 3 months, how many patients have been initiated\* on the following agents for the treatment of melanoma?*

- a. Ipilimumab (monotherapy)*
- b. Nivolumab (monotherapy)*
- c. Nivolumab AND Ipilimumab (combination)*
- d. Pembrolizumab*
- e. Any Targeted Therapy (Dabrafenib /Dabrafenib AND Trametinib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib)*
- f. Other active systemic anti-cancer therapy*

*\*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.*

*Q2. In the last 3 months, how many patients have been initiated\* on the following agents for the treatment of Renal cell carcinoma?*

- a. Nivolumab (monotherapy)*
- b. Nivolumab + Ipilimumab*
- c. Nivolumab + Cabozantinib*
- d. Avelumab + Axitinib*

*\*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.*

*Q3. In the past 3 months, how many patients have been initiated\* on the following agents for treatment for Advanced/Metastatic Oesophageal Cancer:*

- a. Nivolumab monotherapy or in combination with Ipilimumab*
- b. Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)*

*c. Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)*

*\*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.*

Trust response:

Q1

a. 0

b. 0

c. 6

d. 9

e. 5

f. 5

Q2

a. 0

b. 2

c. 0

d. 0

Q3

a. 0

b. 0

c. 1